Opening Asia for Russia

WHO recommends Sinopharm vaccine for emergency use against COVID-19

08.05.2021 37 просмотров

Sinopharm's vaccine is the sixth vaccine to be certified by the WHO for safety and efficacy.

The World Health Organization (WHO) has recommended the Chinese company Sinopharm's vaccine for emergency use against the coronavirus. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, said this at a briefing in Geneva on Friday.

“Today, WHO included in the list of drugs recommended for emergency use against COVID-19 the Beijing Sinopharm vaccine, which is the sixth vaccine to be certified by the WHO for safety, efficacy and quality,” he said. be purchased through the international COVAX mechanism. In addition, the regulatory approval process for the Sinopharm vaccine can be accelerated, and this will allow them to purchase and use it.

Sinopharm, on the WHO emergency list of coronavirus medicines, creates opportunities to “accelerate access to vaccines for countries that want to protect healthcare workers and populations at risk.” “We encourage the manufacturer [Sinopharm] to participate in the COVAX mechanism and help achieve a more equitable distribution of vaccines,” Simao said. drugs: the Comirnaty vaccine, developed jointly by Pfizer from the USA and BioNTech from Germany, a product from Janssen, which is a division of the American Johnson & Johnson, a vaccine by the American company Moderna, and two versions of the vaccine by the British-Swedish company AstraZeneca and the University of Oxford.

COVAX is an international mechanism launched by WHO in conjunction with the Global Alliance for Vaccines and Immunization and the Coalition for Innovation in Preparedness to epidemics. It supports the establishment of production facilities and conducts procurement. Under the terms of the program, high-income countries pay for vaccines for less wealthy countries. Plans call for 2 billion doses of vaccines to be produced and evenly distributed around the world by the end of 2021 under the mechanism.

Новости партнёров